Short-term effect of intensity-modulated radiotherapy for children with high-risk neuroblastoma: an analysis of 24 cases
TANG Zhi-Ge1, CHEN Ke-Ke1, DENG Tan2, LEI Sheng-Fei2, HE Xiang-Ling1
Department of Hematology and Oncology, First Affiliated Hospital of Hunan Normal University/Children's Medical Center of Hunan Provincial People's Hospital, Changsha 410005, China
Abstract Objective To study the efficacy and safety of intensity-modulated radiotherapy (IMRT) in children with high-risk neuroblastoma (NB). Methods A retrospective analysis was performed on the medical data of 24 children with high-risk NB who were diagnosed and treated with IMRT in the Department of Hematology and Oncology, Hunan Provincial People's Hospital, from April 2018 to December 2020. The medical data included age, radiotherapy dose, times of radiotherapy, laboratory examination results, adverse reactions, and survival. Results All 24 children (14 boys and 10 girls) received IMRT, with a mean age of (65±23) months and a median age of 59 months. The primary tumor was located in the abdomen in 23 children and 1 child had primary tumor in the mediastinum. The median age was 41.5 months at the time of radiotherapy. The radiation dose of radiotherapy ranged from 14.4 to 36.0 Gy, with a mean dose of (22±3) Gy and a daily dose of 1.8-2.0 Gy. The radiotherapy was performed for a total number of 8-20 times, with a mean number of 11.9 times. Among these children, 6 received radiotherapy for the residual or metastatic lesion. Of all the 23 children, 3 experienced cough, 2 experienced diarrhea, and 1 experienced vomiting during radiotherapy. At 2 weeks after radiotherapy, serum creatinine ranged from 2.3 to 70.1 μmol/L and alanine aminotransferase ranged from 9.1 to 65.3 μ/L. Ten children experienced grade Ⅲ bone marrow suppression and 2 experienced grade Ⅳ bone marrow suppression 1 to 2 weeks after radiotherapy. Four children experienced grade Ⅲ bone marrow suppression and 1 experienced grade Ⅳ bone marrow suppression 3 to 4 weeks after radiotherapy. During a median follow-up time of 13.5 months, 23 children (96%) achieved stable disease and 1 died. Up to the follow-up date, second malignant tumor or abnormal organ function was not observed. Conclusions IMRT can improve the local control rate of NB. IMRT appears to be safe in the treatment of children with NB.
TANG Zhi-Ge,CHEN Ke-Ke,DENG Tan et al. Short-term effect of intensity-modulated radiotherapy for children with high-risk neuroblastoma: an analysis of 24 cases[J]. CJCP, 2021, 23(6): 621-625.
TANG Zhi-Ge,CHEN Ke-Ke,DENG Tan et al. Short-term effect of intensity-modulated radiotherapy for children with high-risk neuroblastoma: an analysis of 24 cases[J]. CJCP, 2021, 23(6): 621-625.
Cohn SL, Pearson AD, London WB, et al. The International Neuroblastoma Risk Group (INRG) classification system:an INRG task force report[J]. J Clin Oncol, 2009, 27(2):289-297. DOI:10.1200/JCO.2008.16.6785. PMID:19047291.
[9]
Basch E, Becker C, Rogak LJ, et al. Composite grading algorithm for the National Cancer Institute's Patient - Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)[J]. Clin Trials, 2021, 18(1):104-114. DOI:10.1177/1740774520975120. PMID:33258687.
[10]
Howlader N, Noone AM, Yu MD, et al. Use of imputed population-based cancer registry data as a method of accounting for missing information:application to estrogen receptor status for breast cancer[J]. Am J Epidemiol, 2012, 176(4):347-356. DOI:10.1093/aje/kwr512. PMID:22842721.
[11]
Gillis AM, Sutton E, Dewitt KD, et al. Long-term outcome and toxicities of intraoperative radiotherapy for high-risk neuroblastoma[J]. Int J Radiat Oncol Biol Phys, 2007, 69(3):858-864. DOI:10.1016/j.ijrobp.2007.04.006. PMID:17517478.
[12]
Dubois SG, Chesler L, Groshen S, et al. Phase I study of vincristine, irinotecan, and 131I-metaiodobenzylguanidine for patients with relapsed or refractory neuroblastoma:a new approaches to neuroblastoma therapy trial[J]. Clin Cancer Res, 2012, 18(9):2679-2686. DOI:10.1158/1078-0432.CCR-11-3201. PMID:22421195.
[13]
Sidell N. Retinoic acid-induced growth inhibition and morphologic differentiation of human neuroblastoma cells in vitro[J]. J Natl Cancer Inst, 1982, 68(4):589-596. DOI:10.1093/jnci/68.4.589. PMID:7040765.
[14]
Thiele CJ, Reynolds CP, Israel MA. Decreased expression of N-myc precedes retinoic acid-induced morphological differentiation of human neuroblastoma[J]. Nature, 1985, 313(6001):404-406. DOI:10.1038/313404a0. PMID:3855502.
[15]
Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoicacid[J]. N Engl J Med, 1999, 341(16):1165-1173. DOI:10.1056/NEJM199910143411601. PMID:10519894.
[16]
Sait S, Modak S. Anti-GD2 immunotherapy for neuroblastoma[J]. Expert Rev Anticancer Ther, 2017, 17(10):889-904. DOI:10.1080/14737140.2017.1364995. PMID:28780888.
[17]
Mody R, Naranjo A, Van RC, et al. Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221):an open-label, randomised, phase 2 trial[J]. Lancet Oncol, 2017, 18(7):946-957. DOI:10.1016/S1470-2045(17)30355-8. PMID:28549783.
